



## USE/INDICATION

VELSIPITY is a prescription medicine used to treat adults with moderately to severely active ulcerative colitis. It is not known if VELSIPITY is safe and effective in children.

## IMPORTANT SAFETY INFORMATION

**Do not take VELSIPITY if you:**

- have had a heart attack, chest pain (unstable angina), stroke or mini stroke (transient ischemic attack or TIA), and certain types of heart failure requiring hospitalization in the last 6 months
- have or have had a history of unusual heartbeats (arrhythmia) that is not corrected by a pacemaker

Talk to your healthcare provider before taking VELSIPITY if you have any of these conditions or do not know if you have any of these conditions.

**Please see full Prescribing Information and Medication Guide on the last pages or at velsipityPI.com.**


For adults with moderate to severe UC

# Not a steroid. Not a biologic.

# VELSIPITY is one pill, once a day

Some saw remission by Week 12, with fewer bathroom trips and less rectal bleeding

Velsipity®
(etrasimod) 2mg tablets



## A treatment option for moderate to severe UC with safety data* and proven efficacy†

*VELSIPITY safety was studied across 3 different clinical trials and efficacy was studied in 2 trials in people with moderate to severe UC who had trouble tolerating, were not fully responding, or had a loss of response to previous treatments such as steroids, 5-ASAs‡ like mesalamine, biologics, or JAK inhibitors.
†Some saw remission by Week 12 and Week 52. Patients in remission experienced fewer bowel movements and no rectal bleeding.
‡5-ASAs are 5-aminosalicylic acid derivatives.

IMPORTANT SAFETY INFORMATION (cont'd)

**VELSIPITY can cause serious side effects, including:**

- **Infections:** VELSIPITY can increase your risk of serious infections. These infections can be life-threatening and cause death. VELSIPITY lowers the number of white blood cells (lymphocytes) in your blood. This usually returns to normal within 4 to 5 weeks after you stop taking VELSIPITY. Your healthcare provider will test your blood before you start taking VELSIPITY. Your healthcare provider may delay or stop your VELSIPITY treatment if you have an infection. Call your healthcare provider right away if you have any of these symptoms of an infection during treatment with VELSIPITY, and for 5 weeks after you stop taking VELSIPITY: fever or high temperature, pain when peeing or peeing more often than usual as these can be signs of a urinary tract infection, tiredness, flu-like symptoms, or headache with fever, neck stiffness, sensitivity to light, nausea, or confusion as these may be symptoms of meningitis, an infection of the lining around your brain and spine.



IMPORTANT SAFETY INFORMATION (cont'd)

- **Slow heart rate (also known as bradyarrhythmia) when you start taking VELSIPITY:** VELSIPITY may cause your heart rate to temporarily slow down especially after you take your first dose. You will have a test called an electrocardiogram (ECG) to check the electrical activity of your heart before you take your first dose of VELSIPITY. Call your healthcare provider if you experience these symptoms of slow heart rate: feeling dizzy, feeling lightheaded, feeling like your heart is beating slowly or skipping beats, feeling short of breath, feeling confused, feeling tired, or chest pain.

**Please see full Prescribing Information and Medication Guide on the last pages or at velsipityPI.com.**




Velsipity® (etrasimod) 2mg tablets

It's a pill you can take with or without food—it's up to you.

It's a treatment you can take with you. Simply store at room temperature.

Take one tablet of VELSIPITY each day.

**Learn more about VELSIPITY**

IMPORTANT SAFETY INFORMATION (cont'd)

**Before taking VELSIPITY, tell your healthcare provider about all of your medical conditions, including if you:**

- have a serious infection or an infection that does not go away or that keeps coming back (chronic).
- are unable to fight infections due to a disease.
- have received a vaccine in the past 4 weeks or are scheduled to receive a vaccine. You should be brought up to date with all age-required vaccines before starting treatment with VELSIPITY. VELSIPITY may affect how well a vaccine works. Tell your healthcare provider that you are receiving treatment with VELSIPITY before receiving a vaccine.

**Please see full Prescribing Information and Medication Guide on the last pages or at velsipityPI.com.**



IMPORTANT SAFETY INFORMATION (cont'd)

- have chickenpox or received the vaccine for chickenpox. Your healthcare provider may do a blood test for the chickenpox virus. You may need to get the full course of the chickenpox vaccine and then wait 4 weeks before you start taking VELSIPITY.
- have a slow heart rate.
- have an irregular or abnormal heartbeat (arrhythmia).
- have heart disease, Class I or II heart failure, history of a heart attack, high blood pressure or uncontrolled high blood pressure.
- have cerebrovascular disease or history of a stroke or ministroke.

## Efficacy of VELSIPITY® (etrasimod) was studied in 495 people in 2 clinical trials

**In a 3-month study:**

**221** on VELSIPITY

**112** on placebo (a sugar pill)

- Average age on VELSIPITY was 41 years
- 41% female participants

**In a 12-month study:**

**274** on VELSIPITY

**134** on placebo (a sugar pill)

- Average age on VELSIPITY was 41 years
- 45% female participants

VELSIPITY was studied in people with moderate to severe UC across 2 different clinical trials, one lasting 3 months and the other 1 year. These trials looked at the safety and efficacy of VELSIPITY in treating UC, including when therapies like 5-ASAs,* steroids, biologics, or JAK inhibitors weren't working.

# A powerful, once-daily treatment for adults with moderate to severe UC

**32%** of people on VELSIPITY achieved **clinical remission**† at 1 year vs placebo (7%) in the 12-month trial

## Some people on VELSIPITY achieved clinical remission† in just 3 months

**In the 52-week study, at 12 weeks:**

27% VELSIPITY vs 7% placebo

**In the 12-week study:**

26% VELSIPITY vs 15% placebo

*5-ASAs are 5-aminosalicylic acid derivatives.

†Clinical remission means that the symptoms of the disease have improved or disappeared. During remission, you may experience fewer or no episodes of stool frequency and/or rectal bleeding. It's important to remember that remission doesn't mean you are cured, and you still need to follow your doctor's advice to help keep the disease under control and help prevent flare-ups.

### IMPORTANT SAFETY INFORMATION (cont'd)

- history of repeated fainting.
- have or have had liver problems.
- have or have had skin cancer.
- have breathing problems, including untreated sleep apnea.
- are pregnant or plan to become pregnant. VELSIPITY may harm your unborn baby. Talk with your healthcare provider if you are pregnant or plan to become pregnant. If you are a female who can become pregnant, talk with your healthcare provider and use effective birth control during your treatment with VELSIPITY and for 7 days after you stop taking VELSIPITY. If you become pregnant while taking VELSIPITY or within 7 days after you stop taking VELSIPITY, talk with your healthcare provider and enroll in the VELSIPITY Pregnancy Registry by calling 1-800-616-3791.

### IMPORTANT SAFETY INFORMATION (cont'd)

- are breastfeeding or plan to breastfeed. It is not known if VELSIPITY passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take VELSIPITY.

**Tell your healthcare provider about all the medicines you take,** including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using VELSIPITY with other medicines can cause serious side effects. Especially tell your healthcare provider if you take or have taken:

**Please see full Prescribing Information and Medication Guide on the last pages or at velsipityPI.com.**

**For adults with moderate to severe UC**

# VELSIPITY works fast to treat flares, with less frequent bathroom trips at 2 weeks

Some saw remission at Week 12. Some saw fewer bathroom trips in 2 weeks and less rectal bleeding in 4 weeks.

## Visible normalization of the colon lining at 1 year

Visible normalization means that those areas of the colon lining assessed show no visible signs of inflammation or show the disease appears inactive with endoscopy. Areas visually assessed may not represent improvement of the entire colon lining.

**4x** as many people experienced visible normalization of the colon lining with VELSIPITY (26%) vs placebo (6%) at 1 year.

Velsipity® (etrasimod) 2mg tablets

## Proven

Some saw remission* by Week 12 and Week 52

## Fast-Acting

Some saw improvements in stool frequency as early as 2 weeks and less rectal bleeding by 4 weeks

## Long-Lasting

steroid-free remission

100% of patients in clinical remission* with VELSIPITY at 1 year were also steroid-free

*Patients in remission experienced fewer bowel movements and no rectal bleeding.

Don't take VELSIPITY if you've had a heart attack, chest pain, stroke or ministroke, heart failure in the last 6 months, irregular or abnormal heartbeat.

**VELSIPITY can cause serious side effects including:**

- fatal infections
- slow heart rate
- liver problems
- increased blood pressure
- a vision problem called macular edema
- certain types of skin cancer
- swelling and narrowing of brain's blood vessels
- shortness of breath

IMPORTANT SAFETY INFORMATION (cont'd)

- medicines to control your heart rhythm (antiarrhythmics), heartbeat, or blood pressure. These may be called beta blockers or calcium channel blockers.
- medicines that affect your immune system.
- certain medicines known as moderate to strong inhibitors of both CYP2C9 and CYP3A4, medicines such as fluconazole. If you are taking fluconazole, you should not take VELSIPITY.
- Rifampin. If you are taking rifampin, you should not take VELSIPITY.

You should not receive **live** vaccines at least 4 weeks before starting VELSIPITY, during treatment with VELSIPITY and for 5 weeks after you stop taking VELSIPITY. Talk to your healthcare provider before you receive a vaccine during treatment and for 5 weeks after treatment with VELSIPITY. If you receive a live vaccine, you may get the infection the vaccine was meant to prevent. Vaccines may not work as well when given during treatment with VELSIPITY.



IMPORTANT SAFETY INFORMATION (cont'd)

**VELSIPITY can cause serious side effects, including:**

- **Liver problems.** VELSIPITY may cause liver problems. Your healthcare provider will do blood tests to check your liver before you start taking VELSIPITY. Call your healthcare provider right away if you have any of the following symptoms: unexplained nausea, vomiting, stomach area (abdominal pain), tiredness, loss of appetite, yellowing of the whites of your eyes or skin, or dark-colored urine.
- **Increased blood pressure.** Your healthcare provider should check your blood pressure during treatment with VELSIPITY and treat you as needed.
- **A problem with your vision called macular edema.** Your healthcare provider should test your vision around the time you start taking VELSIPITY or at any time you notice vision changes during your treatment with VELSIPITY. Call your healthcare provider right away if you have any of the following symptoms: blurriness or shadows in the center of your vision, sensitivity to light, a blind spot in the center of your vision, or unusually colored vision.

**Please see full Prescribing Information and Medication Guide on the last pages or at velsipityPI.com.**

# VELSIPITY® (etrasimod) demonstrated safety in clinical trials

VELSIPITY should not be taken by patients with certain cardiac conditions such as prior heart attack, chest pain, stroke or heart failure. VELSIPITY can cause serious side effects including infections (some life threatening), a slow heart rate known as bradyarrhythmia, liver problems, increased blood pressure, a vision problem called macular edema, certain types of skin cancer, swelling and narrowing of the blood vessels in your brain, or shortness of breath.

For more information about the safety profile of VELSIPITY, see the Important Safety Information throughout this brochure.

The safety of VELSIPITY was studied in a clinical program with **577 participants taking VELSIPITY across 3 placebo-controlled studies.**

The most common side effects occurring in ≥5% of subjects taking VELSIPITY were **headache, elevated liver tests,** and **dizziness.**

Across two 12-week studies, 6% of people taking VELSIPITY discontinued due to side effects. In the 52-week study, 4% of people taking VELSIPITY discontinued due to side effects.



Your doctor will talk to you about the possibility of side effects, potential for serious infections, and whether VELSIPITY is appropriate for you.



IMPORTANT SAFETY INFORMATION (cont'd)

- **Types of skin cancer.** Certain types of skin cancer have happened with medicines in the same class as VELSIPITY. Limit the amount of time you spend in sunlight and ultraviolet (UV) light while taking VELSIPITY. Wear protective clothing and use a sunscreen with a high sun protection factor. Tell your healthcare provider if you have any changes in the appearance of your skin.
- **Swelling and narrowing of the blood vessels in your brain.** A condition called Posterior Reversible Encephalopathy Syndrome (PRES) has happened with drugs in the same class. Symptoms of PRES usually get better when you discontinue treatment. If not treated, PRES may cause a stroke. Call your healthcare provider right away if you have any of the following symptoms: sudden severe headache, sudden confusion, sudden loss of vision or other changes in your vision, or seizure. If you develop any of these symptoms, your healthcare provider will stop treatment with VELSIPITY.
- **Breathing problems.** Some people who take medicines in the same class as VELSIPITY may experience shortness of breath. Your healthcare provider may do tests to check your breathing during treatment with VELSIPITY. Call your healthcare provider right away if you have new or worsening breathing problems.

**Please see full Prescribing Information and Medication Guide on the last pages or at velsipityPI.com.**

# Savings and flexible support designed to help you

## You could pay as little as $0 per month for your VELSIPITY® (etrasimod) prescription.*

Eligible, commercially insured patients may pay as little as $0 in out-of-pocket costs, with a maximum prescription benefit of $16,000 per calendar year with the Copay Savings Program. Terms and conditions apply.

*Eligibility required. Commercially insured patients only. The maximum prescription benefit offer per patient is $4,000 to $16,000 per calendar year. Patients enrolled in a state or federally funded prescription health insurance program are not eligible. No membership fees. This is not health insurance. Available only to patients who have been diagnosed with an FDA-approved indication for VELSIPITY. Visit VELSIPITY.com for full terms and conditions.




Scan to enroll in the Copay Savings Program or visit VELSIPITY.com/Sign-up

## VelsipityForMe is designed to help you get started on VELSIPITY




Once enrolled in VelsipityForMe, your Dedicated Care Coordinator will be your main point of contact and help guide you through getting started on VELSIPITY.

### Your Dedicated Care Coordinator will:

- **WELCOME** you to VelsipityForMe and go over next steps
- **EXPLAIN** insurance coverage and identify potential financial assistance options
- **COMMUNICATE** with you throughout the process and share updates with your doctor

# Share your VELSIPITY story

**Your voice matters.**

If VELSIPITY has made a difference for you, we would love to hear your story.

Sharing your experience could help others living with moderate to severe UC learn more about VELSIPITY and remind them they are not alone in managing their UC symptoms.



## In order to submit your story, you must be:

- Over 18 years old
- Diagnosed with moderate to severe UC
- Currently taking VELSIPITY
- A US resident

If selected, your story may appear on VELSIPITY.com and/or you may also be invited to participate in various public relations, marketing, and/or promotional activities on behalf of Pfizer. Please also note that patients who opt in will be required to sign release authorization, including a HIPAA form, and provide consent for Pfizer to contact their physicians for additional background information, which may include medical records.

**Share your VELSIPITY story**

Scan the QR code or visit VELSIPITY.com to learn more

You can also email us at MyUCStory@pfizer.com or call 1-800-347-6577.

Velsipity® (etrasimod) 2mg tablets

**Please see full Prescribing Information and Medication Guide on the last pages or at velsipityPI.com.**

Velsipity®
(etrasimod) 2mg tablets




# a once-daily pill for moderate to severe UC

Pfizer

© 2026 Pfizer Inc. All rights reserved.
PP-V1A-USA-1499 June 2026

**IMPORTANT SAFETY INFORMATION (cont'd)**

**The most common side effects of VELSIPITY** include headache, elevated liver tests, and dizziness. These are not all of the possible side effects of VELSIPITY. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Pfizer at 1-800-438-1985.

**Please see full Prescribing Information and Medication Guide on the last pages or at velsipityPI.com.**